EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Renin–Angiotensin System Inhibitor Use and Cancer Incidence Among UK Biobank Participants: A Prospective Cohort Study

Xuyuan Shi, Yi Liu iD, Zelin Ma, Shuxiao Ma, Zihuai Wang, Min Yi, Lunxu Liu iD

Cancer Medicine · 2026-11 · 15 (11)

DOI: 10.1002/cam4.72420 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancer Medicine, online erschienen am 02.11.2026. Verfasst von Xuyuan Shi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme Inhibitors, Neoplasms, Renin-Angiotensin System, Angiotensin Receptor Antagonists. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: 1·3·5 project for disciplines of excellence from West China Hospital of Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Renin‐angiotensin system (RAS) inhibitors may influence cancer incidence, but previous findings have been inconsistent. We aimed to evaluate the associations of RAS inhibitor use with overall and site‐specific cancer incidence. Materials and Methods Participants receiving antihypertensive treatment without prior invasive cancer (except non‐melanoma skin cancer) were identified from the UK Biobank. Individuals with missing covariate data were excluded. Participants were classified as ACEI users, ARB users, or RAS inhibitor non‐users, defined as participants receiving antihypertensive medications other than ACEIs or ARBs. Outcomes included overall cancer incidence and site‐specific cancers. Inverse probability of treatment‐weighted Cox proportional hazards models were applied to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).

Results

Among 94,696 participants followed for a mean of 11.5 years, 42,930 were ACEI users, 17,681 were ARB users, and 34,085 were RAS inhibitor non‐users. No significant associations were observed between ACEI or ARB use and overall cancer incidence. In site‐specific analyses, ARB use showed a modest association with higher prostate cancer incidence compared with ACEI use (HR = 0.90; 95% CI, 0.82–0.99) and RAS inhibitor non‐use (HR = 1.14; 95% CI, 1.02–1.27). ACEI use was associated with lower bladder cancer incidence compared with RAS inhibitor non‐use (HR = 0.71; 95% CI, 0.54–0.93).

Conclusion

RAS inhibitor use was not associated with overall cancer incidence in this large cohort of antihypertensive medication users. Although modest associations were observed between ARB use and prostate cancer incidence and between ACEI use and bladder cancer incidence, these findings should be interpreted cautiously and require confirmation in future studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin-Converting Enzyme InhibitorsNeoplasmsRenin-Angiotensin SystemAngiotensin Receptor AntagonistsAntihypertensive AgentsHumansMaleIncidenceFemaleUnited KingdomMiddle AgedAgedProspective StudiesUK BiobankBiological Specimen Banks

Stichwörter der Autor:innen

UK biobankantihypertensive medicationscancer incidencerenin angiotensin system inhibitors

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive Agents

Autor:innen und Institutionen

  • Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.
  • Institute of Thoracic Oncology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

ORCID-Profile: Yi Liu, Lunxu Liu

Förderung

  • 1·3·5 project for disciplines of excellence from West China Hospital of Sichuan University

Zitieren

APA

Shi, X., Liu, Y., Ma, Z., Ma, S., Wang, Z., Yi, M., & Liu, L. (2026). Renin–Angiotensin System Inhibitor Use and Cancer Incidence Among UK Biobank Participants: A Prospective Cohort Study. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72420

Vancouver

Shi X, Liu Y, Ma Z, Ma S, Wang Z, Yi M, et al. Renin–Angiotensin System Inhibitor Use and Cancer Incidence Among UK Biobank Participants: A Prospective Cohort Study. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72420

BibTeX
@article{Shi2026,
  author = {Shi, Xuyuan and Liu, Yi and Ma, Zelin and Ma, Shuxiao and Wang, Zihuai and Yi, Min and Liu, Lunxu},
  title = {Renin–Angiotensin System Inhibitor Use and Cancer Incidence Among UK Biobank Participants: A Prospective Cohort Study},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1002/cam4.72420}
}
Kostenlos starten →